Examining the Risks and Benefits from Benzodiazepines

Examining the Risks and Benefits from Benzodiazepines

On-Demand Webcast
FACULTY

Rakesh Jain, MD, MPH
Clinical Professor, Department of Psychiatry
Texas Tech Health Sciences Center, School of Medicine
Midland, Texas

Saundra Jain, MA, PsyD, LPC
Private Practice
Austin, Texas
Adjunct Clincial Affliate, School of Nursing
University of Texas at Austin
Austin, Texas

For full faculty bios, please call 609-371-1137.

TO DOWNLOAD SLIDES CLICK HERE.

INTENDED LEARNERS

This activity is intended for psychiatrists, primary care physicians, psychologists, physician assistants, psychiatric nurses, and other healthcare professionals who seek to improve the care of patients with mental health disorders.

LEARNING OBJECTIVES

After completing this activity, participants should be able to:

  • Review emerging data on abuse potential, dementia risk, and black box warning associated with benzodiazepines
  • Assess the risk–benefit profile of benzodiazepines, and discuss how to most prudently utilize these medications in clinical practice
  • Describe various pathways through which harm reduction with benzodiazepines can be enacted
ACTIVITY OVERVIEW

To be eligible for documentation of credit, participants must participate in the full activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. Participants who successfully complete the post-test and evaluation form online may immediately print their documentation of credit.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

Release Date: 11/1/2017
Expiration Date: 12/31/2018
Estimated time to complete: 1.25 hours

For questions regarding this educational activity, please call 609-371-1137.

ACCREDITATION INFORMATION

In support of improving patient care, North American Center for Continuing Medical Education, LLC (NACCME) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

CME

NACCME designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE

This continuing nursing education activity awards 1.50 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.50 contact hours.

PHARMACOLOGY CREDITS

This continuing nursing educational activity awards up to 1.25 pharmacology hours.

CE INFORMATION: APA

North American Center for Continuing Medical Education, LLC (NACCME) is approved by the American Psychological Association to sponsor continuing education for psychologists. NACCME maintains responsibility for this program and its content.

Instructional Level: Advanced

PLANNING COMMITTEE

The planning committee comprises Douglas L. Noordsy, MD; Eric Arauz, MLER; James Cannon, PhD, MS, PA-C, CAQ-Psy, DFAAPA; Julie Carbray, PhD, FPMHNP, PMHCNS; Jon W. Draud, MD, MS; Rakesh Jain, MD, MPH; Saundra Jain, MA, PsyD, LPC; Catherine Judd, MS, PA-C, CAQ-Psy, DFAAPA; Vladimir Maletic, MD, MS; Andrew Penn, RN, MS, NP, CNS, APRN-BC; Charles L. Raison, MD; and Raquel Gaerlan, Jennifer Ilcyn, Meaghan Benci, Randy Robbin, John Savage, Kelly Sweeney, and Stephanie Weiss.

Independent Clinical Reviewer: Douglas L. Noordsy, MD, Clinical Professor of Psychiatry & Behavioral Sciences, Stanford University School of Medicine; Director of Sports Psychiatry, Department of Psychiatry & Behavioral Sciences, Stanford University, Stanford, California

Nurse Planner: Andrew Penn, RN, MS, NP, CNS, APRN-BC, Psychiatric Nurse Practitioner, Kaiser Permanente, Redwood City, CA; Assistant Clinical Professor, University of California, San Francisco, CA

FINANCIAL DISCLOSURE AND CONFLICTS OF INTEREST

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty reported the following:

Dr. Cannon: Consultant—Shire Advisory Board

Dr. Rakesh Jain: Advisory Board—Addrenex, Alkermes, Avanir, Forum, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer, Shionogi, Shire, Sunovion, Supernus, Takeda, and Teva; Consultant—Addrenex, Allergan, Avanir, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer, Shionogi, Shire, Sunovion, Supernus, Takeda, Teva; Consultant (spouse)—Lilly, Otsuka, Pamlab, Sunovion; Grant/Research Support—AstraZeneca, Allergan, Lilly, Lundbeck, Otsuka, Pfizer, Shire, Takeda; Speakers’ Bureau—Addrenez, Alkermes, Allergan, Lilly, Lundbeck, Merck, Neos Therapeutics, Otsuka, Pamlab, Pfizer, Rhodes, Shionogi, Shire, Sunovion, Takeda, and Tris Pharmaceuticals

Dr. Saundra Jain: Consultant (self)—Lilly, Otsuka, Pamlab, Sunovion; Spouse: Advisory Board—Addrenex, Alkermes, Avanir, Forum, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer, Shionogi, Shire, Sunovion, Supernus, Takeda, Teva; Consultant—Addrenex, Allergan, Avanir, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer, Shionogi, Shire, Sunovion, Supernus, Takeda, Teva; Grant—Allergan, AstraZeneca, Lilly, Lundbeck, Otsuka, Pfizer, Shire, Takeda; Promotional Speakers’ Bureau—Addrenex, Alkermes, Allergan, Lilly, Lundbeck, Merck, Neos Therapeutics, Otsuka, Pamlab, Pfizer, Rhodes, Shionogi, Shire, Sunovion, Takeda, Tris Pharmaceuticals; Research Support—Allergan, AstraZeneca, Lilly, Lundbeck, Otsuka, Pfizer, Shire, Takeda

Dr. Maletic: Consultant—Lundbeck A/S, Merck & Co., Inc., Otsuka America Pharmaceutical, Inc., Sunovion Pharmaceuticals Inc., Supernus Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd.; Speaking Honoraria—Allergan, H. Lundbeck A/S, Merck & Co., Inc., Otsuka America Pharmaceutical, Inc., Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited; Speakers Honoraria (spouse)—Otsuka, Psych U (CME)

Dr. Raison: Consultant—Usona Institute, Emory Healthcare; Advisory Board—Otsuka, Lundbeck

Mr. Arauz, Dr. Carbray, Dr. Draud, Ms. Judd, Dr. Noordsy, Mr. Penn, and, Dr. Torrey have disclosed no relevant financial relationships with any commercial interests.

Ms. Gaerlan, Ms. Ilcyn, Ms. Benci, Mr. Robbin, Mr. Savage, Ms. Sweeney and Ms. Weiss have disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The off-label use of carbamazepine, pregabalin, and gabapentin to help with benzodiazepine taper and withdrawal will be discussed.

HARDWARE/SOFTWARE REQUIREMENTS

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

PRIVACY POLICY

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2017 by North American Center for Continuing Medical Education, LLC (NACCME). All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from NACCME. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.